性别决定因子17在胰腺癌组织中的表达及其对预后的影响分析  

Analysis of the expression of SRY-box transcription factor 17 in pancreatic cancer tissue and its effect on prognosis

作　　者：卢迪[1] 李雪龙 张晓云[1] 金桐[1] 刘心娟[1] 郝建宇[1] Lu Di;Li Xuelong;Zhang Xiaoyun;Jin Tong;Liu Xinjuan;Hao Jianyu(Department of Gastroenterology,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院消化内科,北京100020

出　　处：《临床内科杂志》2023年第3期175-179,共5页Journal of Clinical Internal Medicine

摘　　要：目的在组织水平探讨性别决定因子17(SOX17)在胰腺癌中的表达及其对预后的影响。方法纳入人胰腺导管腺癌组织(癌组织组)85例和配对癌旁组织(癌旁组织组)68例。收集全部芯片组织来源患者的临床资料并分组进行比较。采用受试者工作特征(ROC)曲线下面积(AUC)评估SOX17对胰腺癌的诊断价值,采用Kaplan-Meier生存分析评价SOX17表达与患者生存期的关系,采用Cox回归分析评估胰腺癌预后的危险因素。结果免疫组化染色发现SOX17主要定位于癌细胞的胞浆。癌组织组SOX17高表达率显著高于癌旁组织组(P<0.001)。ROC曲线分析结果显示,SOX17高表达诊断胰腺癌的AUC为0.83,对应敏感度及特异度分别为86.76%、78.82%。SOX17低表达癌组织组T1~T2分期患者比例高于SOX17高表达癌组织组;SOX17低表达癌旁组织组年龄<65岁、2型糖尿病病史患者比例均低于SOX17高表达癌旁组织组,合并脉管侵犯患者比例高于SOX17高表达癌旁组织组(P<0.05)。SOX17高表达癌旁组织组年龄<65岁及2型糖尿病病史患者比例均高于SOX17高表达癌组织组,合并脉管侵犯患者比例低于SOX17高表达癌组织组;SOX17低表达癌旁组织组T1~T2分期患者比例低于SOX17低表达癌组织组(P<0.05)。Kaplan-Meier生存分析结果显示,癌组织组和癌旁组织组SOX17表达与患者总生存期无关(P>0.05),癌组织组SOX17高表达与淋巴结转移及美国癌症联合委员会(AJCC)分期Ⅲ~Ⅳ期患者的不良预后均相关(P=0.04);癌旁组织组SOX17高表达与否认吸烟及饮酒史患者的不良预后均相关(P=0.04)。Cox回归分析结果显示,病理分级高和否认吸烟史均为胰腺癌患者预后的独立危险因素(P<0.05)。结论SOX17在胰腺癌组织中的表达高于癌旁组织,其表达对患者的总生存期无显著影响,但对合并淋巴结转移等情况的患者预后具有提示作用。Objective To explore the expression of SRY-box transcription factor 17(SOX17)in pancreatic cancer and its effect on prognosis at the tissue level.Methods A total of 85 human pancreatic ductal adenocarcinoma tissues(cancer tissue group)and 68 matched paracancerous tissues(adjacent tissue group)were included.The clinical data of patients were collected and compared between the two groups.The area under receiver operating characteristic(ROC)curve(AUC)was used to evaluate the diagnostic value of SOX17 for pancreatic cancer.Kaplan-Meier survival analysis was used to evaluate the relationship between SOX17 expression and patient survival,and Cox regression analysis was used to evaluate the risk factors of pancreatic cancer prognosis.Results Immunohistochemical staining showed that SOX17 was mainly located in the cytoplasm of cancer cells.The high expression rate of SOX17 in the cancer tissue group was significantly higher than that in the adjacent tissue group(P<0.001).ROC curve analysis showed that AUC of SOX17 high expression for pancreatic cancer diagnosis was 0.83,and the corresponding sensitivity and specificity were 86.76%and 78.82%.The proportion of T1-T2 stage patients in the SOX17 low expression cancer tissue group was lower than that in the SOX17 high expression cancer tissue group.The proportions of patients under 65 years old and with history of type 2 diabetes in the SOX17 low expression adjacent tissue group were lower than those in the SOX17 high expression adjacent tissue group,while the proportion of patients with vascular invasion was higher(P<0.05).The proportions of patients under 65 years old and with history of type 2 diabetes in SOX17 high expression adjacent tissue group were higher than those in the SOX17 high expression cancer tissue group,while the proportion of patients with vasculature invasion was lower.The proportions of T1-T2 stage patients in the SOX17 low expression adjacent tissue group was higher than that in the SOX17 low expression cancer tissue group(P<0.05).Kaplan-Meier survival

关 键 词：胰腺癌 性别决定因子17 免疫组织化学 总生存期 

分 类 号：R735.9[医药卫生—肿瘤]